Intercept Pharmaceuticals
Clinical trials sponsored by Intercept Pharmaceuticals, explained in plain language.
-
Halted trial tests drug to protect young livers
Disease control TerminatedThis study tested whether a medication called obeticholic acid could help children with biliary atresia after they had a successful Kasai surgery. The goal was to see if the drug, given alongside standard care, could delay serious liver problems like needing a transplant or hospi…
Phase: PHASE2, PHASE3 • Sponsor: Intercept Pharmaceuticals • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New drug duo tested for tough liver disease
Disease control TerminatedThis study tested whether combining two drugs, obeticholic acid and bezafibrate, could better control Primary Biliary Cholangitis (PBC), a chronic liver disease. It was for patients whose standard treatment wasn't working well or who couldn't tolerate it. The main goal was to see…
Phase: PHASE2 • Sponsor: Intercept Pharmaceuticals • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
Trial tests Long-Term safety of promising liver disease drug duo
Disease control TerminatedThis study aimed to check the long-term safety and side effects of a fixed-dose pill combining two drugs, obeticholic acid and bezafibrate, for people with primary biliary cholangitis (PBC), a chronic liver disease. It was an open-label extension study for 63 participants who had…
Phase: PHASE3 • Sponsor: Intercept Pharmaceuticals • Aim: Disease control
Last updated Mar 16, 2026 15:24 UTC